MX2020007580A - Compuestos de 1,2,3',5'-tetrahidro-2'h-espiro[indol-3,1'-pirrolo[3 ,4-c]pirrol]-2,3'-diona como agentes terapeuticos que activan a p53. - Google Patents

Compuestos de 1,2,3',5'-tetrahidro-2'h-espiro[indol-3,1'-pirrolo[3 ,4-c]pirrol]-2,3'-diona como agentes terapeuticos que activan a p53.

Info

Publication number
MX2020007580A
MX2020007580A MX2020007580A MX2020007580A MX2020007580A MX 2020007580 A MX2020007580 A MX 2020007580A MX 2020007580 A MX2020007580 A MX 2020007580A MX 2020007580 A MX2020007580 A MX 2020007580A MX 2020007580 A MX2020007580 A MX 2020007580A
Authority
MX
Mexico
Prior art keywords
pyrrolo
pyrrole
tetrahydro
spiro
indole
Prior art date
Application number
MX2020007580A
Other languages
English (en)
Inventor
Marcin Feder
Iwona Kalinowska
Wojciech Lewandowski
Maria Mazur
Katarzyna Wos-Latosi
Joanna Jaszczewska-Adamczak
Jakub Witkowski
Sabina Jelen
Original Assignee
Adamed Pharma S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Pharma S A filed Critical Adamed Pharma S A
Publication of MX2020007580A publication Critical patent/MX2020007580A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invencion se refiere a compuestos de 1,2,3',5'-tetrahidro-2?-es piro[indol-3,1'- pirrolo[3,4-c]pirrol]-2,3'-diona representados por la formula (I): (ver Formula) en donde todos los simbolos y variables son como se definen en la descripcion; los compuestos puedenencontrar uso en un metodo de prevencion y/o tratamiento de enfermedades seleccionadas del grupo que consiste en cancer, enfermedades inmunes, condiciones inflamatorias, enfermedades alergicas de la piel asociadas con la proliferacion excesiva, enfermedad cegadora e infecciones virales.
MX2020007580A 2018-01-16 2019-01-09 Compuestos de 1,2,3',5'-tetrahidro-2'h-espiro[indol-3,1'-pirrolo[3 ,4-c]pirrol]-2,3'-diona como agentes terapeuticos que activan a p53. MX2020007580A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18461506.0A EP3511334A1 (en) 2018-01-16 2018-01-16 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp53
PCT/EP2019/050370 WO2019141549A1 (en) 2018-01-16 2019-01-09 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp53

Publications (1)

Publication Number Publication Date
MX2020007580A true MX2020007580A (es) 2020-11-18

Family

ID=60997409

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007580A MX2020007580A (es) 2018-01-16 2019-01-09 Compuestos de 1,2,3',5'-tetrahidro-2'h-espiro[indol-3,1'-pirrolo[3 ,4-c]pirrol]-2,3'-diona como agentes terapeuticos que activan a p53.

Country Status (25)

Country Link
US (1) US20200354372A1 (es)
EP (2) EP3511334A1 (es)
JP (1) JP7284190B2 (es)
KR (1) KR20200110322A (es)
CN (1) CN111566110B (es)
AU (1) AU2019209114B2 (es)
BR (1) BR112020014427A2 (es)
CA (1) CA3086440A1 (es)
CY (1) CY1125134T1 (es)
DK (1) DK3740492T3 (es)
EA (1) EA202091718A1 (es)
ES (1) ES2911229T3 (es)
HR (1) HRP20220458T1 (es)
HU (1) HUE058461T2 (es)
IL (1) IL276006B2 (es)
LT (1) LT3740492T (es)
MX (1) MX2020007580A (es)
PL (1) PL3740492T3 (es)
PT (1) PT3740492T (es)
RS (1) RS63123B1 (es)
SG (1) SG11202006048PA (es)
SI (1) SI3740492T1 (es)
UA (1) UA127457C2 (es)
WO (1) WO2019141549A1 (es)
ZA (1) ZA202004972B (es)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070213341A1 (en) * 2006-03-13 2007-09-13 Li Chen Spiroindolinone derivatives
US7834179B2 (en) * 2007-05-23 2010-11-16 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US7776875B2 (en) * 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
US7723372B2 (en) 2008-03-19 2010-05-25 Hoffman-La Roche Inc. Spiroindolinone derivatives
US8076482B2 (en) * 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
US8088815B2 (en) * 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8217044B2 (en) * 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
US20120071499A1 (en) * 2010-09-20 2012-03-22 Xin-Jie Chu Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones
UY33725A (es) * 2010-11-12 2012-06-29 Sanofi Sa Antagonistas de mdm2 de espiro-oxindol
PL2684880T3 (pl) * 2011-03-10 2018-07-31 Daiichi Sankyo Company, Limited Pochodna dispiropirolidyny
SG194873A1 (en) 2011-05-11 2013-12-30 Sanofi Sa Spiro-oxindole mdm2 antagonists
WO2013080141A1 (en) 2011-11-29 2013-06-06 Novartis Ag Pyrazolopyrrolidine compounds
UY34591A (es) * 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
MX2016013457A (es) * 2014-04-17 2017-05-04 Univ Michigan Regents Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
KR20170012559A (ko) 2014-06-12 2017-02-02 아다메드 에스피. 제트 오.오. P53-mdm2 단백질-단백질 상호작용 억제제로서 1,1'',2,5''-테트라하이드로스피로[인돌-3,2''-피롤]-2,5''-디온계를 포함하는 화합물
JP6503386B2 (ja) * 2014-07-03 2019-04-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＭＤＭ２−ｐ５３阻害剤としての新しいスピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン化合物および誘導体
ES2959097T3 (es) * 2014-08-18 2024-02-20 Hudson Biopharma Inc Espiropirrolidinas como inhibidores de MDM2
ES2739697T3 (es) * 2014-08-21 2020-02-03 Boehringer Ingelheim Int Nuevos compuestos y derivados de espiro[3H-indol-3,2-pirrolidin]-2(1H)-ona como inhibidores de MDM2-p53
CA3000063A1 (en) * 2015-10-09 2017-04-13 Boehringer Ingelheim International Gmbh Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
CN105585570B (zh) * 2015-12-15 2019-10-15 贵州大学 异恶唑拼接吡咯螺环氧化吲哚化合物及其制备方法及应用
CN105669683B (zh) * 2015-12-28 2020-06-16 徐州医学院 一类吲哚螺吡咯衍生物的合成及其作为肿瘤治疗药物的应用
CN106008532B (zh) * 2016-07-20 2019-06-07 贵州大学 烷氧基嘧啶拼接3-吡咯螺环氧化吲哚衍生物及其制备方法及应用

Also Published As

Publication number Publication date
AU2019209114B2 (en) 2022-12-08
HUE058461T2 (hu) 2023-09-28
EP3511334A1 (en) 2019-07-17
KR20200110322A (ko) 2020-09-23
JP2021512141A (ja) 2021-05-13
CN111566110A (zh) 2020-08-21
CA3086440A1 (en) 2019-07-25
SG11202006048PA (en) 2020-08-28
JP7284190B2 (ja) 2023-05-30
RS63123B1 (sr) 2022-05-31
EP3740492B1 (en) 2022-03-02
ZA202004972B (en) 2021-08-25
PT3740492T (pt) 2022-04-13
IL276006B (en) 2022-11-01
BR112020014427A2 (pt) 2020-12-01
WO2019141549A1 (en) 2019-07-25
PL3740492T3 (pl) 2022-08-08
AU2019209114A1 (en) 2020-07-09
CY1125134T1 (el) 2024-02-16
US20200354372A1 (en) 2020-11-12
EA202091718A1 (ru) 2020-10-27
WO2019141549A9 (en) 2019-10-10
SI3740492T1 (sl) 2022-05-31
HRP20220458T1 (hr) 2022-05-27
ES2911229T3 (es) 2022-05-18
UA127457C2 (uk) 2023-08-30
EP3740492A1 (en) 2020-11-25
DK3740492T3 (da) 2022-04-19
LT3740492T (lt) 2022-05-10
IL276006A (en) 2020-08-31
CN111566110B (zh) 2023-04-25
IL276006B2 (en) 2023-03-01

Similar Documents

Publication Publication Date Title
PH12018500958A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
MX2020005054A (es) Combinacion de dos agentes antivirales para el tratamiento de hepatitis c.
MA39985B1 (fr) 1h-pyrrolo [2,3-c]pyridine -7(6h)-ones et pyrazolo[3,4-c]pyridine-7(6h)-ones en tant qu'inhibiteurs de protéines bet
MX2016012799A (es) Metodos para tratar el virus de la hepatitis c.
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
MX2021001096A (es) 7-bencil-4-(2-metilbencilo)-2,4,6,7,8,9-hexahidroimidazo [1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, analogos y sales del mismo y su uso en terapia.
PH12019501371A1 (en) PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORy AND OTHERS USES
EA030564B9 (ru) СОЕДИНЕНИЯ, СОДЕРЖАЩИЕ СИСТЕМУ 1,1',2,5'-ТЕТРАГИДРОСПИРО[ИНДОЛ-3,2'-ПИРРОЛ]-2,5'-ДИОНА В КАЧЕСТВЕ ИНГИБИТОРОВ БЕЛОК-БЕЛКОВОГО ВЗАИМОДЕЙСТВИЯ p53-Mdm2
MX2015012536A (es) Combinacion de agentes antivirales de accion directa y ribavirina para el tratamiento de pacientes con vhc.
PH12020550230A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2020081879A3 (en) 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING α-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS
SG10201810660QA (en) Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
MX2022006086A (es) Derivados de piridopirimidinona como antagonistas de ahr.
MX2016015761A (es) Derivados de amina de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor.
MX2018000240A (es) Metodos para tratar el vhc.
EP3804764A4 (en) TREATMENT OF HER2 MUTANT CANCER BY ADMINISTRATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE
MX2023007998A (es) Regimenes de tratamiento con dexmedetomidina.
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
PH12018500697A1 (en) Hydroxyalkyl thiadiazole derivatives
WO2023097194A3 (en) Bicyclic therapeutic compounds and methods of use in the treatment of cancer
MX2016012722A (es) Metodos para tratar el virus de la hepatitis c.
MX2020007580A (es) Compuestos de 1,2,3',5'-tetrahidro-2'h-espiro[indol-3,1'-pirrolo[3 ,4-c]pirrol]-2,3'-diona como agentes terapeuticos que activan a p53.
CA2855719C (en) Apoaequorin for reducing neuronal injury due to ischemia
AU2018277958A8 (en) 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative
MX2019015731A (es) Tratamiento de carcinoma hepatocelular caracterizado por infeccion por virus de hepatitis b.